Related Experiment Video

Updated: Aug 15, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Clinical trials of amodiaquine in onchocerciasis

O O Kale

    Bulletin of the World Health Organization
    |January 1, 1982
    PubMed

    Insights

    Amodiaquine treatment showed no effectiveness against Onchocerca volvulus (river blindness) in Nigerian patients. The drug was poorly tolerated and is concluded to be ineffective for treating human onchocerciasis.

    Area of Science:

    • Medical Parasitology
    • Tropical Medicine
    • Pharmacology

    Background:

    • Onchocerciasis, also known as river blindness, is a debilitating parasitic disease prevalent in tropical regions.
    • Effective treatments are crucial for controlling the spread and impact of Onchocerca volvulus infections.

    Purpose of the Study:

    • To evaluate the efficacy of amodiaquine in treating human onchocerciasis.
    • To assess the tolerability of amodiaquine in patients with Onchocerca volvulus infection.

    Main Methods:

    • Twenty patients diagnosed with onchocerciasis from Western Nigeria were enrolled.
    • Amodiaquine was administered at total dosages ranging from 22 to 68 mg/kg over 2-9 days.

    Main Results:

    • Amodiaquine demonstrated no activity against microfilariae or adult Onchocerca volvulus.
    • Twelve out of twenty patients experienced poor tolerability to the drug.

    Conclusions:

    • Amodiaquine is ineffective in treating human onchocerciasis.
    • The drug's poor tolerability further supports its unsuitability for this indication.

    More Related Videos

    Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors05:28

    Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors

    Published on: May 12, 2022

    Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds07:14

    Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

    Published on: July 11, 2025

    Related Concept Videos

    Clinical Trials01:16

    Clinical Trials

    Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
    There are four phases in a clinical trial. A phase one...
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
    Preclinical Development: Overview01:28

    Preclinical Development: Overview

    Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
    American Trypanosomiasis01:22

    American Trypanosomiasis

    Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
    Anthelminthic Agents01:15

    Anthelminthic Agents

    Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
    Antiprotozoal Agents01:21

    Antiprotozoal Agents

    Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...